Persistent improvement in synaptic and cognitive functions in an Alzheimer mouse model after rolipram treatment

Journal of Clinical Investigation

Volumn 114, Issue 11, 2004, Pages 1624-1634

  Gong, Bing ^a,b   Vitolo, Ottavio V ^b   Trinchese, Fabrizio ^a,c   Liu, Shumin ^a,c   Shelanski, Michael ^b   Arancio, Ottavio ^a,b,c  

^a NATHAN S KLINE INSTITUTE FOR PSYCHIATRIC RESEARCH   (United States)

^b Och Spine at New York Presbyterian Hospitals   (United States)

^c NEW YORK UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

AMYLOID BETA PROTEIN[1-42]; AMYLOID PRECURSOR PROTEIN; CYCLIC AMP DEPENDENT PROTEIN KINASE; CYCLIC AMP RESPONSIVE ELEMENT BINDING PROTEIN; PHOSPHODIESTERASE IV INHIBITOR; PRESENILIN 1; ROLIPRAM; MEMBRANE PROTEIN; PHOSPHODIESTERASE INHIBITOR; PSEN1 PROTEIN, HUMAN;

ALZHEIMER DISEASE; AMINO ACID SUBSTITUTION; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; ASSOCIATIVE MEMORY; BRAIN PROTECTION; COGNITION; COGNITIVE DEFECT; CONTROLLED STUDY; DISEASE MODEL; DRUG MECHANISM; ENZYME ACTIVATION; FEMALE; GENE EXPRESSION; LEARNING; LONG TERM CARE; LONG TERM POTENTIATION; MALE; MEMORY DISORDER; MOUSE; NONHUMAN; PRIORITY JOURNAL; SIGNAL TRANSDUCTION; SYNAPSE; SYNAPTIC TRANSMISSION; SYSTEMIC THERAPY; TRANSGENIC MOUSE; TREATMENT OUTCOME; WORKING MEMORY; ANIMAL; CYTOLOGY; DRUG EFFECT; GENETICS; HIPPOCAMPUS; HUMAN; IN VITRO STUDY; METABOLISM; PATHOPHYSIOLOGY; PHYSIOLOGY;

ALZHEIMER DISEASE; AMYLOID BETA-PROTEIN PRECURSOR; ANIMALS; COGNITION; CYCLIC AMP RESPONSE ELEMENT-BINDING PROTEIN; DISEASE MODELS, ANIMAL; HIPPOCAMPUS; HUMANS; LEARNING; LONG-TERM POTENTIATION; MALE; MEMBRANE PROTEINS; MICE; MICE, TRANSGENIC; PHOSPHODIESTERASE INHIBITORS; PRESENILIN-1; ROLIPRAM; SYNAPTIC TRANSMISSION;

EID: 85047694516     PISSN: 00219738     EISSN: None     Source Type: Journal    
DOI: 10.1172/JCI22831     Document Type: Article

References (60)

1. Masliah, E. 1995. Mechanisms of synaptic dysfunction in Alzheimer's disease. Histol. Histopathol. 10:509-519.
2. Cullen, W.K., Suh, Y.H., Anwyl, R., and Rowan, M.J. 1997. Block of LTP in rat hippocampus in vivo by beta-amyloid precursor protein fragments. Neuroreport. 8:3213-3217.
3. Itoh, A., et al. 1999. Impairments of long-term potentiation in hippocampal slices of beta-amyloid-infused rats. Eur. J. Pharmacol. 382:167-175.
4. Vitolo, O.V., et al. 2002. Amyloid beta-peptide inhibition of the PKA/CREB pathway and long-term potentiation: reversibility by drugs that enhance cAMP signaling. Proc. Natl. Acad. Sci. U. S. A. 99:13217-13221.
5. Walsh, D.M., et al. 2002. Naturally secreted oligomers of amyloid beta protein potently inhibit hippocampal long-term potentiation in vivo. Nature. 416:535-539.
6. Bliss, T.V., and Collingridge, G.L. 1993. A synaptic model of memory: long-term potentiation in the hippocampus. Nature. 361:31-39.
7. Barad, M. 2003. Later developments: molecular keys to age-related memory impairment. Alzheimer Dis. Assoc. Disord. 17:168-176.
8. Zhang, H.T., Crissman, A.M., Dorairaj, N.R., Chandler, L.J., and O'Donnell, J.M. 2000. Inhibition of cyclic AMP phosphodiesterase (PDE4) reverses memory deficits associated with NMDA receptor antagonism. Neuropsychopharmacology. 23:198-204.
9. Zhang, H.T., and O'Donnell, J.M. 2000. Effects of rolipram on scopolamine-induced impairment of working and reference memory in the radial-arm maze tests in rats. Psychopharmacology (Berl.). 150:311-316.
10. Imanishi, T., et al. 1997. Ameliorating effects of rolipram on experimentally induced impairments of learning and memory in rodents. Eur. J. Pharmacol. 321:273-278.
11. Zhang, H.T., et al. 2004. Inhibition of the phosphodiesterase 4 (PDE4) enzyme reverses memory deficits produced by infusion of the MEK inhibitor U0126 into the CA1 subregion of the rat hippocampus. Neuropsychopharmacology. 29:1432-1439.
12. Barad, M., Bourtchouladze, R., Winder, D.G., Golan, H., and Kandel, E. 1998. Rolipram, a type IV-specific phosphodiesterase inhibitor, facilitates the establishment of long-lasting long-term potentiation and improves memory. Proc. Natl. Acad. Sci. U. S. A. 95:15020-15025.
13. Nagakura, A., Niimura, M., and Takeo, S. 2002. Effects of a phosphodiesterase IV inhibitor rolipram on microsphere embolism-induced defects in memory function and cerebral cyclic AMP signal transduction system in rats. Br. J. Pharmacol. 135:1783-1793.
14. Bourtchouladze, R., et al. 2003. A mouse model of Rubinstein-Taybi syndrome: defective long-term memory is ameliorated by inhibitors of phosphodiesterase 4. Proc. Natl. Acad. Sci. U. S. A. 100:10518-10522.
15. Nicholson, C.D. 1990. Pharmacology of nootropics and metabolically active compounds in relation to their use in dementia. Psychopharmacology (Berl.). 101:147-159.
16. Ramos, B.P., et al. 2003. Dysregulation of protein kinase A signaling in the aged prefrontal cortex: new strategy for treating age-related cognitive decline. Neuron. 40:835-845.
17. Arendash, G.W., et al. 2001. Progressive, age-related behavioral impairments in transgenic mice carrying both mutant amyloid precursor protein and presenilin-1 transgenes. Brain Res. 891:42-53.
18. Battaglia, F., et al. 2003. Calpain inhibitors, a treatment for Alzheimer's disease: position paper. J. Mol. Neurosci. 20:357-362.
19. Trinchese, F., et al. 2004. Progressive age-related development of Alzheimer-like pathology in APP/PS1 mice: early impairment of long-term potentiation and short-term memory associated with amyloid-beta production and plaque deposition. Ann. Neurol. 55:801-814.
20. Krause, W., and Kuhne, G. 1988. Pharmacokinetics of rolipram in the rhesus and cynomolgus monkeys, the rat and the rabbit. Studies on species differences. Xenobiotica. 18:561-571.
21. Phillips, R., and LeDoux, J. 1992. Differential contribution of amygdala and hippocampus to cued and contextual fear conditioning. Behav. Neurosci. 106:274-285.
22. Bourtchuladze, R., et al. 1994. Deficient long-term memory in mice with a targeted mutation of the cAMP-responsive element-binding protein. Cell. 79:59-68.
23. Tully, T., Bourtchouladze, R., Scott, R., and Tallman, J. 2003. Targeting the CREB pathway for memory enhancers. Nat. Rev. Drug Discov. 2:267-277.
24. Dineley, K.T., Xia, X., Bui, D., Sweatt, J.D., and Zheng, H. 2002. Accelerated plaque accumulation, associative learning deficits, and up-regulation of alpha 7 nicotinic receptor protein in transgenic mice co-expressing mutant human presenilin 1 and amyloid precursor proteins. J. Biol. Chem. 277:22768-22780.
25. Corcoran, K.A., Lu, Y., Turner, R.S., and Maren, S. 2002. Overexpression of hAPPswe impairs rewarded alternation and contextual fear conditioning in a transgenic mouse model of Alzheimer's disease. Learn. Mem. 9:243-252.
26. Morgan, D., et al. 2000. A beta peptide vaccination prevents memory loss in an animal model of Alzheimer's disease. Nature. 408:982-985.
27. Lustbader, J.W., et al. 2004. ABAD directly links Abeta to mitochondrial toxicity in Alzheimer's disease. Science. 304:448-452.
28. Petrone, A., et al. 2003. Receptor protein tyrosine phosphatase alpha is essential for hippocampal neuronal migration and long-term potentiation. EMBO J. 22:4121-4131.
29. Diamond, D.M., Park, C.R., Heman, K.L., and Rose, G.M. 1999. Exposing rats to a predator impairs spatial working memory in the radial arm water maze. Hippocampus. 9:542-552.
30. Morris, R., Garrud, P., Rawlins, J., and O'Keefe, J. 1982. Place navigation impaired in rats with hippocamal lesions. Nature. 297:681-683.
31. Sutherland, R.J., Kolb, B., and Whishaw, I.Q. 1982. Spatial mapping: definitive disruption by hippocampal or medial frontal cortical damage in the rat. Neurosci. Lett. 31:271-276.
32. Schenk, F., and Morris, R.G. 1985. Dissociation between components of spatial memory in rats after recovery from the effects of retrohippocampal lesions. Exp. Brain Res. 58:11-28.
33. Yin, J.C., et al. 1994. Induction of a dominant negative CREB transgene specifically blocks long-term memory in Drosophila. Cell. 79:49-58.
34. Bach, M.E., et al. 1999. Age-related defects in spatial memory are correlated with defects in the late phase of hippocampal long-term potentiation in vitro and are attenuated by drugs that enhance the cAMP signaling pathway. Proc. Natl. Acad Sci. U. S. A. 96:5280-5285.
35. Navakkode, S., Sajikumar, S., and Frey, J.U. 2004. The type IV-specific phosphodiesterase inhibitor rolipram and its effect on hippocampal long-term potentiation and synaptic tagging. J. Neurosci. 24:7740-7744.
36. Nakagawa, S., et al. 2002. Regulation of neurogenesis in adult mouse hippocampus by cAMP and the cAMP response element-binding protein. J. Neurosci. 22:3673-3682.
37. Dodart, J.C., et al. 2002. Immunization reverses memory deficits without reducing brain Abeta burden in Alzheimer's disease model. Nat. Neurosci. 5:452-457.
38. Iwatsubo, T., Mann, D.M., Odaka, A., Suzuki, N., and Ihara, Y. 1995. Amyloid beta protein (A beta) deposition: A beta 42(43) precedes A beta 40 in Down syndrome. Ann. Neurol. 37:294-299.
39. Oddo, S., et al. 2003. Triple-transgenic model of Alzheimer's disease with plaques and tangles: intracellular Abeta and synaptic dysfunction. Neuron. 39:409-421.
40. LaFerla, F.M., Troncoso, J.C., Strickland, D.K., Kawas, C.H., and Jay, G. 1997. Neuronal cell death in Alzheimer's disease correlates with apoE uptake and intracellular Aβ stabilization. J. Clin. Invest. 100:310-320.
41. Gouras, G.K., et al. 2000. Incraneuronal Abeta42 accumulation in human brain. Am. J. Pathol. 156:15-20.
42. Dragunow, M. 2004. CREB and neurodegeneration. Front. Biosci. 9:100-103.
43. Weeber, E.J., and Sweatt, J.D. 2002. Molecular neurobiology of human cognition. Neuron. 33:845-848.
44. Tong, J., Hannan, F., Zhu, Y., Bernards, A., and Zhong, Y. 2002. Neurofibromin regulates G protein-stimulated adenylyl cyclase activity. Nat. Neurosci. 5:95-96.
45. Andersen, S.L., Arvanitogiannis, A., Pliakas, A.M., LeBlanc, C., and Carlezon, W.A., Jr. 2002. Altered responsiveness to cocaine in rats exposed to methylphenidate during development. Nat. Neurosci. 5:13-14.
46. Perez, J., et al. 2000. Abnormalities of cAMP signaling in affective disorders: implication for pathophysiology and treatment. Bipolar Disord. 2:27-36.
47. Einat, H., et al. 2003. The role of the extracellular signal-regulated kinase signaling pathway in mood modulation. J. Neurosci. 23:7311-7316.
48. Nehlig, A., Daval, J.L., and Debry, G. 1992. Caffeine and the central nervous system: mechanisms of action, biochemical, metabolic and psychostimulant effects. Brain Res. Brain Res. Rev. 17:139-170.
49. Gevaerd, M.S., Takahashi, R.N., Silveira, R., and Da Cunha, C. 2001. Caffeine reverses the memory disruption induced by intra-nigral MPTP-injection in rats. Brain Res. Bull. 55:101-106.
50. Angelucci, M.E., et al. 1999. The effect of caffeine in animal models of learning and memory. Eur. J. Pharmacol. 373:135-140.
51. Castellano, C. 1976. Effects of caffeine on discrimination learning, consolidation, and learned behavior in mice. Psycho pharmacology (Berl.). 48:255-260.
52. Schenk, D., et al. 1999. Immunization with amyloid-beta attenuates Alzheimer-disease-like pathology in the PDAPP mouse. Nature. 400:173-177.
53. Lombardo, J.A., et al. 2003. Amyloid-beta antibody treatment leads to rapid normalization of plaque-induced neuritic alterations. J. Neurosci. 23:10879-10883.
54. Ferrer, I., Boada Rovira, M., Sanchez Guerra, M.L., Rey, M.J., and Costa-Jussa, F. 2004. Neuropathology and pathogenesis of encephalitis following amyloid-beta immunization in Alzheimer's disease. Brain Pathol. 14:11-20.
55. Nicoll, J.A., et al. 2003. Neuropathology of human Alzheimer disease after immunization with amyloid-beta peptide: a case report. Nat. Med. 9:448-452.
56. Hebenstreit, G.F., et al. 1989. Rolipram in major depressive disorder: results of a double-blind comparative study with imipramine. Pharmacopsychiatry. 22:156-160.
57. Dal Piaz, V., and Giovannoni, M.P. 2000. Phosphodiesterase 4 inhibitors, structurally unrelated to rolipram, as promising agents for the treatment of asthma and other pathologies. Eur. J. Med. Chem. 35:463-480.
58. Hsiao, K., et al. 1996. Correlative memory deficits, Abeta elevation, and amyloid plaques in transgenic mice. Science. 274:99-102.
59. Duff, K., et al. 1996. Increased amyloid-beta42(43) in brains of mice expressing mutant presenilin 1. Nature. 383:710-713.
60. Barad, M., Bourtchouladze, R., Winder, D.G., Golan, H., and Kandel, E. 1998. Rolipram, a type IV-specific phosphodiesterase inhibitor, facilitates the establishment of long-lasting long-term potentiation and improves memory. Proc. Natl. Acad. Sci. U. S. A. 95:15020-15025.